Discounted Cash Flow Rating

Sell

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Simple Moving Average

Strong Buy

Exponential Moving Average

Strong Buy

Relative Strength Index

Neutral

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Buy

Wall Street Data Solutions Rating

Buy

A

UroGen Pharma Ltd. Ordinary Shares (URGN)

Pharmaceutical Preparations

https://www.urogen.com

UroGen Pharma Ltd is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative solutions that treat urothelial and specialty cancers. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Its lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy.

9 HA'TA'ASIYA ST
RA'ANANA, L3

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

05/04/2017

Market Cap

627,500,090

Shares Outstanding

30,870,000

Weighted SO

30,866,320

Total Employees

N/A

Upcoming Earnings

08/08/2024

Similar Tickers

ELYM --.--%

INBX --.--%

MACK --.--%

CELC --.--%

ELVN --.--%

IKNA --.--%

XLO --.--%

TARA --.--%

SRRK --.--%

Beta

1.1230

Last Div

0.0000

Range

10.6-20.92

Chg

-0.5900

Avg Vol

661722

Mkt Cap

627500090

Exch

NASDAQ

Country

US

Phone

646 768 9780

DCF Diff

14.9047

DCF

-0.4447

Div Yield

0.0000

P/S

7.3814

EV Multiple

-6.5401

P/FV

18.0988

Div Yield %

0.0000

P/E

-4.8303

PEG

-0.1866

Payout

0.0000

Current Ratio

8.1515

Quick Ratio

7.9340

Cash Ratio

6.4517

DSO

74.7724

DIO

315.4855

Op Cycle

390.2579

DPO

352.5790

CCC

37.6789

Gross Margin

0.8987

Op Margin

-0.9374

Pretax Margin

-1.2898

Net Margin

-1.3361

Eff Tax Rate

-0.0359

ROA

-0.4030

ROE

3.8824

ROCE

-0.3218

NI/EBT

1.0359

EBT/EBIT

1.3760

EBIT/Rev

-0.9374

Debt Ratio

0.3499

D/E

3.2529

LT Debt/Cap

0.7634

Total Debt/Cap

0.7649

Int Coverage

-6.7010

CF/Debt

-0.8353

Equity Multi

9.2977

Rec Turnover

4.8815

Pay Turnover

1.0352

Inv Turnover

1.1569

FA Turnover

46.4541

Asset Turnover

0.3016

OCF/Share

-2.2368

FCF/Share

-2.2414

Cash/Share

6.5695

OCF/Sales

-0.9689

FCF/OCF

1.0020

CF Coverage

-0.8353

ST Coverage

-103.4723

CapEx Coverage

-488.6822

Div&CapEx Cov

-488.6822

P/BV

18.0988

P/B

18.0988

P/S

7.3814

P/E

-4.8303

P/FCF

-7.6031

P/OCF

-6.6612

P/CF

-6.6612

PEG

-0.1866

P/S

7.3814

EV Multiple

-6.5401

P/FV

18.0988

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jun 24, 01:00 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Reckitt, UroGen and Fortrea and Encourages Investors to Contact the Firm GlobeNewswire Inc. Jun 17, 01:00 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Reckitt, UroGen and Fortrea and Encourages Investors to Contact the Firm GlobeNewswire Inc. Jun 14, 11:48 IOVA SHAREHOLDERS: Iovance Biotherapeutics, Inc. Investors are Reminded of the Pending Securities Fraud Class Action – Contact BFA Law by July 14 Deadline (NASDAQ:IOVA) GlobeNewswire Inc. Jun 14, 11:48 URGN SHAREHOLDERS: UroGen Pharma Ltd. Investors are Reminded of the Pending Securities Fraud Class Action – Contact BFA Law by July 28 Deadline (NASDAQ:URGN) GlobeNewswire Inc. Jun 10, 01:00 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against UroGen, Strategy Incorporated, and Organon and Encourages Investors to Contact the Firm GlobeNewswire Inc. Jun 06, 22:21 URGN Investors with Large Losses Should Contact Robbins LLP for Information About the Class Action Lawsuit Against UroGen Pharma Ltd. GlobeNewswire Inc. Jun 06, 21:48 UroGen Pharma Ltd. (URGN) Faces Securities Class Action Amid FDA’s Briefing Document and Subsequent ODAC Vote Against UGN-102– Hagens Berman GlobeNewswire Inc. Jun 06, 00:00 Kirby McInerney LLP Reminds UroGen Pharma Ltd. (URGN) Investors of Class Action Filing and Encourages Investors to Contact the Firm GlobeNewswire Inc. Jun 03, 01:00 UROGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against UroGen Pharma Ltd. and Encourages Investors to Contact the Firm GlobeNewswire Inc. May 29, 22:46 UroGen Pharma Ltd. Investors: Please contact the Portnoy Law Firm to recover your losses. July 28, 2025 Deadline to file Lead Plaintiff Motion. GlobeNewswire Inc. May 29, 22:44 Rocket Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm GlobeNewswire Inc. May 29, 22:39 Tempus AI, Inc. Investors: Company Investigated by the Portnoy Law Firm Benzinga May 16, 22:33 Securities Fraud Investigation Into UroGen Pharma Ltd. (URGN) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Revenue Product Segmentation